Anavex Life Sciences Corp (AVXL)

[nidan7500]

JJ

If we only get data on the 5 or 6 strong responders. With a few outliers and no data on the rest of the 19. And nothing about the dropouts

I assume we will have data on all patients in the study, if that is 19 great. I also assume if 5 or 6 respond then the remaining pts will be on to further analysis. I expect that is how this process will work. In fact I would amazed if everyone responded similarly in some envelope.

I expect this discovery-analysis process will/may go on and on, but it is all we got and this AD branch will need to be completed. We should expect the PM process to require dispositioning of all people in the trials. So then, in that context the questions are different for me.

-Who will and how will the patients who are strong responders be followed?-Will all other responders be assigned to an inspection/analysis process which evaluates HOW they are different from those who responded and what to do about it.

I hope we understand that this is only the beginning of the PM process being applied to CNS diseases. The value of AVXL in W/S terms (aside from partnerships) should be driven by their control of CNS disease analysis process model as much as by the products sold. IMO, Dr.M. and his team are driven by the CNS homeostasis model, not only one trial.